Previous 10 | Next 10 |
Galmed (NASDAQ: GLMD ): Q1 GAAP EPS of -$0.29 beats by $0.08 . More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel , May 14, 2020 /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoh...
TEL AVIV, Israel , May 7, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the tre...
Galmed Pharmaceuticals Ltd (GLMD) Q4 2019 Earnings Conference Call March 12, 2020 8:30 AM ET Company Participants Allen Baharaff - Chairman, CEO & President Yohai Stenzler - CFO & Controller Liat Hayardeny - Chief Scientific Officer Conference Call Participants Yasm...
Galmed (NASDAQ: GLMD ): Q4 GAAP EPS of -$0.39 misses by $0.03 . More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel , March 12, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in a Phase 3 clinical trial f...
In my previous article regarding NASH disease and the potential winners of the first wave drugs, I made a comparison of efficacy of the late stage drug candidates which have better chances to be first in the market of NASH. For those who are interested, please click here . In this article, ...
Galmed Pharmaceuticals (NASDAQ: GLMD ) resumed with Overweight rating and $14 (142% upside) price target at Cantor Fitzgerald. More news on: Madrigal Pharmaceuticals, Inc., Xencor, Inc., Spring Bank Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
A company with research centered around each of these divisions, like a cluster of trees each growing additional branches form its own trunk, will usually do much better than a company working on a number of unrelated new products which, if successful, will land it in several new industries ...
The new year has a collection of challenges in store for the biotech sector and its investors, as pressure mounts from Washington on drug pricing practices. Along with talking points surrounding the upcoming presidential election in the US, several drug approvals and research developments wi...
News, Short Squeeze, Breakout and More Instantly...
Galmed Pharmaceuticals Ltd. Company Name:
GLMD Stock Symbol:
NASDAQ Market:
Galmed Pharmaceuticals Ltd. Website: